129 related articles for article (PubMed ID: 34284481)
1. 68Ga-PSMA PET/CT to Distinguish Brain Metastasis of Renal Cell Carcinoma From Radiation Necrosis After Stereotactic Radiosurgery.
Filizoglu N; Cetin IA; Kissa TN; Niftaliyeva K; Ones T
Clin Nucl Med; 2021 Nov; 46(11):913-914. PubMed ID: 34284481
[TBL] [Abstract][Full Text] [Related]
2. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
3. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
[TBL] [Abstract][Full Text] [Related]
4. 68Ga-PSMA Uptake Patterns of Clear Cell Renal Carcinoma Across Different Histopathological Subtypes.
Oflas M; Ozluk Y; Sanli O; Ozkan ZG; Kuyumcu S
Clin Nucl Med; 2022 Jan; 47(1):e45-e46. PubMed ID: 34284482
[TBL] [Abstract][Full Text] [Related]
5. De Quervain Subacute Thyroiditis With Moderate PSMA Uptake Mimicking Thyroid Metastasis of Renal Cell Carcinoma.
Leder T; Drescher R; Gühne F; Theis B; Freesmeyer M
Clin Nucl Med; 2022 Mar; 47(3):221-222. PubMed ID: 34690294
[TBL] [Abstract][Full Text] [Related]
6.
Tom MC; DiFilippo FP; Jones SE; Suh JH; Obuchowski NA; Smile TD; Murphy ES; Yu JS; Barnett GH; Angelov L; Mohammadi AM; Huang SS; Wu G; Johnson S; Peereboom DM; Stevens GHJ; Ahluwalia MS; Chao ST
J Neurooncol; 2023 Jul; 163(3):647-655. PubMed ID: 37341842
[TBL] [Abstract][Full Text] [Related]
7. Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
Has Simsek D; Civan C; Erdem S; Sanli Y
Clin Nucl Med; 2021 Jul; 46(7):579-581. PubMed ID: 33782292
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-PSMA Uptake in Brain Metastasis of Gastric Carcinoma.
Kesim S; Oksuzoglu K
Clin Nucl Med; 2022 Sep; 47(9):e585-e586. PubMed ID: 35930713
[TBL] [Abstract][Full Text] [Related]
9. Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patients.
Lehrer EJ; Ahluwalia MS; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Jones BM; Green S; Sheehan JP; Trifiletti DM
J Neurosurg; 2023 May; 138(5):1178-1187. PubMed ID: 36115055
[TBL] [Abstract][Full Text] [Related]
10. Metastasis-directed Therapy (SBRT) Guided by PET-CT
Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
[TBL] [Abstract][Full Text] [Related]
11. Use of 18 F-PSMA PET to Distinguish Cerebral Radiation Necrosis From Tumor Recurrence.
Rayamajhi SJ; Ponisio MR; Siegel B
Clin Nucl Med; 2023 Oct; 48(10):e483-e484. PubMed ID: 37486317
[TBL] [Abstract][Full Text] [Related]
12. Pathologic complete response in renal cell carcinoma brain metastases treated with stereotactic radiosurgery.
Teh BS; Bloch C; Paulino AC; Shen S; Hinckley L; Baskin D; Butler EB; Amato R
Clin Genitourin Cancer; 2007 Jun; 5(5):334-7. PubMed ID: 17645831
[TBL] [Abstract][Full Text] [Related]
13. Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
Sadeq A; Usmani S; Esmail AA; Fathallah W; Alfeeli MA; Marafi F
Clin Nucl Med; 2022 Jul; 47(7):627-628. PubMed ID: 35675136
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases.
Marko NF; Angelov L; Toms SA; Suh JH; Chao ST; Vogelbaum MA; Barnett GH; Weil RJ
World Neurosurg; 2010 Mar; 73(3):186-93; discussion e29. PubMed ID: 20860956
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive evaluation of
Gao J; Xu Q; Fu Y; He K; Zhang C; Zhang Q; Shi J; Zhao X; Wang F; Guo H
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):561-569. PubMed ID: 32623502
[TBL] [Abstract][Full Text] [Related]
16. The use of
Raveenthiran S; Esler R; Yaxley J; Kyle S
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2280-2288. PubMed ID: 31332498
[TBL] [Abstract][Full Text] [Related]
17. [
Meng L; Zhang S; Gao J; Xu Q; Fu Y; Zhou YH; Wang F; Guo H
Eur Radiol; 2022 Sep; 32(9):6545-6553. PubMed ID: 35357538
[TBL] [Abstract][Full Text] [Related]
18.
Parghane RV; Basu S
J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
[TBL] [Abstract][Full Text] [Related]
19. Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
Li Y; Zheng R; Zhang Y; Huang C; Tian L; Liu R; Liu Y; Zhang Z; Han H; Zhou F; He L; Dong P
Int J Cancer; 2023 Jan; 152(1):42-50. PubMed ID: 35751420
[TBL] [Abstract][Full Text] [Related]
20. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
